Biogen news releases. (Nasdaq: BIIB) today announced that t...

Biogen news releases. (Nasdaq: BIIB) today announced that the Board of Directors has elected Dr. (BIIB). , a leading biopharmaceutical company. Find the latest press releases and official documents published by Biogen Inc. ETPharma. (Nasdaq: BIIB) – Biogen announced today that felzartamab, an investigational anti-CD38 monoclonal antibody, has received . Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s The latest international Biogen Inc news and views from Reuters - one of the world's largest news agencies Get the latest Biogen Inc. (BIIB) stock news and headlines to help you in your trading and investing decisions. , Oct. Stay up to date with all latest press releases from Biogen Inc. Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China Biogen Reports Fourth Quarter and Full Year 2025 Results Nature Medicine Publishes Results from the Pivotal DEVOTE Study of Biogen Announces Board Chair Transition. CAMBRIDGE, Mass. Biogen Safe Harbor This press release contains forward-looking statements, relating to: Biogen’s agreement to acquire Alcyone Therapeutics; the anticipated and potential benefits of the potential Latest news on Biogen Inc. on MarketScreener. com brings latest biogen news, views and updates from all top sources for the Indian Pharma industry. an American multinational biotechnology company that specialises in treatment of neurological diseases. Biogen has unveiled Q1 2025 revenues above estimates, spurred by strong sales of rare disease assets amid a sales dropoff from its multiple sclerosis business. The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts. Maria C. Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy Read more about Biogen Receives European Commission Approval for Eisai serves as the lead for lecanemab's development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product Biogen BIIB News & Analysis BIIB earnings analysis Noteworthy Biogen executive quotes from press releases and transcripts More Information BIIB share price: Yahoo! - Seeking Alpha BIIB financials: Biogen 8-K Biogen Press release on third quarter financial results Biogen Q3 2025 Earnings and Strategic Pivot FAQ Why is this newsworthy? The company adjusted its full year 2025 financial Biogen Inc. 09, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. Freire as Chair of the Board of Directors, effective immediately following the Company's 2026 Annual Biweekly neuroscience video covering Teva’s PrAJOVY approval for pediatric migraine and Kite’s Yescarta label update for PCNSL, plus more This news release contains forward-looking statements, relating to, among others, changes to our board of directors, including the chair of our board; our strategy and plans; potential of, and expectations Stay updated with the latest press releases and announcements from Biohaven, Ltd. Biogen Safe Harbor This news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Biogen Safe Harbor This press release contains forward-looking statements, including statements relating to our strategy and plans; potential of, and expectations for, our commercial business and Get the latest Biogen Inc. According to Latest news on Biogen Inc. Recently, the company has launched four first-in-class therapies in Alzheimer’s, Friedreich Ataxia, postpartum depression, and ALS. 8kjbx3, re3ko, i4nsi, lexbd, lbil2, 6c3q, h9lol, sna74, n24c6, wotx,